Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(13E)-11alpha-hydroxy-9,15-dioxoprost-13-enoate + NADPH + H+
11alpha-hydroxy-9,15-dioxoprostanoate + NADP+
-
-
-
?
(5S,12R)-dihydroxy-(6E,8Z,10Z,14E)-eicosatetraenoic acid + NADH
?
(5S,6R)-dihydroxy-15-oxo-(7E,9E,11Z,13E)-eicosatetraenoic acid + NADH
13,14-dihydro-(5S,6R)-dihydroxy-15-oxo-(7E,9E,11Z)-eicosatetraenoic acid + NAD+
-
trivial name 15-oxo-lipoxin A4
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
(Z)-3-[(5-methoxy-3-oxo-2(3H)-benzofuranylidene)-methyl]benzoic acid + NAD(P)H
3-[(5-methoxy-3-oxo-2,3-dihydro-1-benzofuran-2-yl)methyl]benzoic acid + NAD(P)+
-
-
-
?
1-(p-carboxyphenyl)-5-cyano-3-oxo-1-pentene + NAD(P)H
1-(p-carboxyphenyl)-5-cyano-3-oxo-pentane + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NADPH
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NADP+
-
-
-
-
?
11alpha-hydroxy-9,15-dioxoprostanoate + NAD(P)+
(13E)-11alpha-hydroxy-9,15-dioxoprost-13-enoate + NAD(P)H + H+
-
-
-
?
15-ketoprostaglandin A1 + NAD(P)H
?
15-ketoprostaglandin B1 + NAD(P)H
?
15-ketoprostaglandin E + NAD(P)H
?
15-ketoprostaglandin E1 + NADH + H+
13,14-dihydro-15-keto-prostaglandin E1 + NAD+
15-ketoprostaglandin E1 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E1 + NAD+
-
-
-
-
r
15-ketoprostaglandin E1 + NADPH
?
15-ketoprostaglandin E1 + reduced nicotinamide hypoxanthine dinucleotide + H+
13,14-dihydro-15-keto-prostaglandin E1 + nicotinamide hypoxanthine dinucleotide
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADPH
?
-
-
-
-
?
15-ketoprostaglandin E2 + NADPH + H+
13,14-dihydro-15-keto-prostaglandin E2 + NADP+
-
-
-
?
15-ketoprostaglandin E2 + reduced nicotinamide hypoxanthine dinucleotide + H+
13,14-dihydro-15-ketoprostaglandin E2 + nicotinamide hypoxanthine dinucleotide
-
93% activity compared to NADH
-
-
r
15-ketoprostaglandin F1alpha + NAD(P)H
?
15-ketoprostaglandin F1alpha + NADPH
?
-
-
-
?
15-ketoprostaglandin F2alpha + NADPH
?
15-oxoprostaglandin F1alpha + NAD(P)H
?
3-nonen-2-one + NADPH
nonane-2-one + NADP+
-
-
-
?
3-penten-2-one + NADPH
pentane-2-one + NADP+
-
-
-
?
4-hydroxy-2-hexenal + NADPH
4-hydroxyhexanal + NADP+
-
-
-
?
4-hydroxy-2-nonenal + NADPH
4-hydroxynonanal + NADP+
-
-
-
?
4-hydroxy-2-nonenal + NADPH
?
-
-
-
-
?
6,15-diketo-prostaglandin F1alpha + NAD(P)H
?
-
-
-
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
acrolein + NADPH
propanal + NADP+
-
-
-
?
alpha-methylcinnamaldehyde + NADPH
?
-
-
-
-
?
benzylidene acetone + NADPH
?
-
-
-
-
?
benzylidene acetonphenone + NADPH
?
-
-
-
-
?
beta-ionone + NAD(P)H
?
-
-
-
-
?
chalcone + NADPH
?
-
-
-
-
?
cinnamaldehyde + NADPH
?
-
-
-
-
?
cinnamoylthiophene + NADPH
?
-
-
-
-
?
curcumin + NAD(P)H
?
-
-
-
-
?
ethylvinylketone + NADPH
pentane-3-one + NADP+
-
-
-
?
methyl vinyl ketone + NADPH
?
-
-
-
-
?
phenyl propenyl ketone + NADPH
?
-
-
-
-
?
prostaglandin E2 + NADP+
15-ketoprostaglandin E2 + NADPH + H+
-
-
-
-
?
trans,trans-2,4-nonadienal + NADPH + H+
?
-
-
-
-
r
trans-2-(o-hydroxybenzylidene)acetophenone + NAD(P)H
(o-hydroxybenzyl)acetophenone + NAD(P)+
-
-
-
?
trans-2-benzylidenecyclohexan-2-one + NAD(P)H
benzylcyclohexan-2-one + NAD(P)+
-
-
-
?
trans-2-butenal + NAD(P)H
butanal + NAD(P)+
trans-2-decenal + NADPH
decanal + NADP+
-
-
-
?
trans-2-decenal + NADPH + H+
decanal + NADP+
-
-
-
?
trans-2-dodecenal + NADPH
dodecanal + NADP+
-
-
-
?
trans-2-hexenal + NAD(P)H
hexanal + NAD(P)+
trans-2-hexenal + NADPH
?
-
-
-
-
?
trans-2-nonenal + NADPH
nonanal + NADP+
-
-
-
?
trans-2-octenal + NADPH
octanal + NADP+
-
-
-
?
trans-2-pentenal + NADPH
pentanal + NADP+
-
-
-
?
trans-3-(2-furyl)acrolein + NAD(P)H
2-furylpropanal + NAD(P)+
-
-
-
?
trans-3-nonen-2-one + NADPH + H+
? + NADP+
-
-
-
?
trans-4-furyl-3-buten-2-one + NAD(P)H
4-furyl-butane-2-one + NAD(P)+
-
-
-
?
trans-benzylideneacetone + NAD(P)H
benzylacetone + NAD(P)+
trans-benzylideneacetophenone + NAD(P)H
benzylacetophenone + NAD(P)+
-
-
-
?
trans-cinnamaldehyde + NAD(P)H
?
-
-
-
-
?
trans-cinnamic acid ethyl ester + NAD(P)H
?
-
-
-
-
?
trans-cinnamoyl thiophene + NAD(P)H
?
-
-
-
-
?
trans-methylvinylketone + NAD(P)H
butane-2-one + NAD(P)+
trans-phenyl-1-propenyl ketone + NAD(P)H
phenylpropane-1-one + NAD+
-
-
-
?
trans-trans-2,4-hexadienal + NAD(P)H
?
-
-
-
-
?
additional information
?
-
(5S,12R)-dihydroxy-(6E,8Z,10Z,14E)-eicosatetraenoic acid + NADH
?
-
15-keto-prostaglandin-13-reductase activity is 200fold higher than leukotrien B4-12hydroxydehydrogenase activity
-
-
?
(5S,12R)-dihydroxy-(6E,8Z,10Z,14E)-eicosatetraenoic acid + NADH
?
-
trivial name leukotriene B4, enzyme exhibits a 15-ketoprostaglandin-13-reductase and a very low leukotriene B4 12-hydroxydehydrogenase activity
-
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
no substrate: prostaglandin E1
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
no substrates: 15-hydroxyprostaglandins, progesterone, cortisone, orotic acid, fumaric acid
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
no substrates: 15-hydroxyprostaglandins, progesterone, cortisone, orotic acid, fumaric acid
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
55% of activity with 15-keto-prostaglandin E2
-
ir
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
?
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NAD(P)H
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoate + NAD(P)+
-
-
-
ir
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
i.e. 15-ketoprostaglandin E2
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
?
11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid + NAD(P)H
11-hydroxy-9,15-dioxoprosta-5-en-1-oic acid + NAD(P)+
-
-
-
-
?
15-ketoprostaglandin A1 + NAD(P)H
?
-
-
-
-
?
15-ketoprostaglandin A1 + NAD(P)H
?
-
108% of activity with 15-keto-prostaglandin E2
-
-
?
15-ketoprostaglandin B1 + NAD(P)H
?
-
-
-
-
?
15-ketoprostaglandin B1 + NAD(P)H
?
-
79% of activity with 15-keto-prostaglandin E2
-
-
?
15-ketoprostaglandin E + NAD(P)H
?
-
-
-
-
?
15-ketoprostaglandin E + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-ketoprostaglandin E + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-ketoprostaglandin E + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-ketoprostaglandin E1 + NADH + H+
13,14-dihydro-15-keto-prostaglandin E1 + NAD+
-
-
-
-
r
15-ketoprostaglandin E1 + NADH + H+
13,14-dihydro-15-keto-prostaglandin E1 + NAD+
-
-
-
-
r
15-ketoprostaglandin E1 + NADPH
?
-
-
-
-
?
15-ketoprostaglandin E1 + NADPH
?
-
-
-
-
?
15-ketoprostaglandin E1 + NADPH
?
-
-
-
?
15-ketoprostaglandin E1 + NADPH
?
-
-
-
-
?
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
-
-
-
r
15-ketoprostaglandin E2 + NADH + H+
13,14-dihydro-15-ketoprostaglandin E2 + NAD+
-
100% activity
-
-
r
15-ketoprostaglandin F1alpha + NAD(P)H
?
-
-
-
-
?
15-ketoprostaglandin F1alpha + NAD(P)H
?
-
-
-
-
?
15-ketoprostaglandin F2alpha + NADPH
?
-
-
-
-
?
15-ketoprostaglandin F2alpha + NADPH
?
-
-
-
?
15-ketoprostaglandin F2alpha + NADPH
?
-
-
-
-
?
15-oxoprostaglandin F1alpha + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-oxoprostaglandin F1alpha + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
15-oxoprostaglandin F1alpha + NAD(P)H
?
-
second step in metabolism of E- and Falpha-type prostaglandins
-
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
56% of activity with 15-keto-prostaglandin E2
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
i.e. 15-ketoprostaglandin F2alpha
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
i.e. 15-ketoprostaglandin F2alpha
-
?
9,11-dihydroxy-15-oxoprosta-5,13-dien-1-oic acid + NAD(P)H
9,11-dihydroxy-15-oxoprosta-5-en-1-oic aicd + NAD(P)+
-
i.e. 15-ketoprostaglandin F2alpha
-
?
leukotriene B4 + NADPH
?
-
-
-
-
?
leukotriene B4 + NADPH
?
-
-
-
-
?
trans-2-butenal + NAD(P)H
butanal + NAD(P)+
-
-
-
?
trans-2-butenal + NAD(P)H
butanal + NAD(P)+
-
-
-
?
trans-2-hexenal + NAD(P)H
hexanal + NAD(P)+
-
-
-
?
trans-2-hexenal + NAD(P)H
hexanal + NAD(P)+
-
-
-
?
trans-benzylideneacetone + NAD(P)H
benzylacetone + NAD(P)+
-
-
-
?
trans-benzylideneacetone + NAD(P)H
benzylacetone + NAD(P)+
-
-
-
?
trans-methylvinylketone + NAD(P)H
butane-2-one + NAD(P)+
-
-
-
?
trans-methylvinylketone + NAD(P)H
butane-2-one + NAD(P)+
-
-
-
?
additional information
?
-
-
essential enzyme for eicosanoid inactivation
-
-
?
additional information
?
-
PGR1, which catalyzes the NADPH-dependent reduction of the alpha,beta-double bond of aliphatic and aromatic aldehydes and ketones, and 15-keto-prostaglandins. PGR1 also shows low activity in the oxidation of leukotriene B4. The best substrates in terms of kcat/Km are 15-keto-prostaglandins, trans-3-nonen-2-one, and trans-2-decenal. Molecular docking simulations, role of Arg56 and Tyr245 in 15-keto-prostaglandin binding, overview
-
-
?
additional information
?
-
-
PGR1, which catalyzes the NADPH-dependent reduction of the alpha,beta-double bond of aliphatic and aromatic aldehydes and ketones, and 15-keto-prostaglandins. PGR1 also shows low activity in the oxidation of leukotriene B4. The best substrates in terms of kcat/Km are 15-keto-prostaglandins, trans-3-nonen-2-one, and trans-2-decenal. Molecular docking simulations, role of Arg56 and Tyr245 in 15-keto-prostaglandin binding, overview
-
-
?
additional information
?
-
not active towards 6-keto-prostaglandin F1alpha, prostaglandin F2beta, 11beta-prostaglandin F2alpha, 13,14-dihydro-15-keto-prostaglandin D2, 13,14-dihydro-15-keto-prostaglandin E2, 13,14-dihydro-15-keto-PGF2alpha, and leukotriene B4
-
-
?
additional information
?
-
bifunctional enzyme capable of inactivating leukotriene B4 and 15-oxo-prostaglandins, enzyme plays a role in growth suppressive functions in lung cancer
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
13,14-dihydro-15-prostaglandin E2
-
competitive product inhibition
15-keto prostaglandin F2alpha
-
43.06% residual activity at 0.1 mM
5-(2-chloro-3-((4-methylcyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(1-cyclopropylethoxy)benzylidene)-1,3- thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(2-cyclohexylethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(3-cyclohexylpropoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione
-
the compound significantly increases the level of PGE2 in skin defects
5-(2-chloro-3-(4-cyclohexylbutoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(cyclohexylmethoxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(cyclohexyloxy)benzylidene)thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-(cyclopentyloxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
-
5-(2-chloro-3-phenethoxybenzylidene)thiazolidine-2,4-dione
-
-
5-(3-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione
-
-
5-(3-(bicyclo[2.2.1]hept-2-ylmethoxy)-2-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
-
-
benzylidene acetophenone
-
21.09% residual activity at 0.5 mM
Disulfiram
-
0.1 mM, 61% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2
NADH
-
uncompetitive inhibition at high concentrations
Cibacron blue 3 G-A
-
competitive inhibition vs. NADH, noncompetitive vs. 15-keto-prostaglandin E2
dicoumarol
-
0.1 mM, 86% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2
dicoumarol
-
0.1 mM, complete inhibition
dicoumarol
-
11.45% residual activity at 0.1 mM
indomethacin
-
0.1 mM, 97% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2
indomethacin
-
0.1 mM, 95% inhibition
indomethacin
-
14.22% residual activity at 0.1 mM
NADPH
-
competitive inhibition vs. NADH, noncompetitive vs. 15-keto-prostaglandin E2
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
0.1 mM, complete inhibition
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
0.0001 mM, 85% inhibition
p-chloromercuribenzoate
-
0.1 mM, 97% inhibition
quercitrin
-
0.1 mM, 76% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2
quercitrin
-
95% inhibition
quercitrin
-
13.14% residual activity at 0.1 mM
additional information
evaluation of non-steroidal anti-inflammatory drugs (NSAIDs) as enzyme potential inhibitors
-
additional information
-
evaluation of non-steroidal anti-inflammatory drugs (NSAIDs) as enzyme potential inhibitors
-
additional information
-
thiazolidinediones as enzyme inhibitors. No inhibition by 5-(2-chloro-3-(1-cyclopropylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
-
additional information
-
finasteride has no inhibitory effect
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00014
5-(2-chloro-3-((4-methylcyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00013
5-(2-chloro-3-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00109
5-(2-chloro-3-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00023
5-(2-chloro-3-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00017
5-(2-chloro-3-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.0103
5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000029
5-(2-chloro-3-(2-cyclohexylethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00015
5-(2-chloro-3-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000059
5-(2-chloro-3-(3-cyclohexylpropoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00014
5-(2-chloro-3-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000045
5-(2-chloro-3-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000095
5-(2-chloro-3-(4-cyclohexylbutoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.0117
5-(2-chloro-3-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000054
5-(2-chloro-3-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00036
5-(2-chloro-3-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000058
5-(2-chloro-3-(cyclohexylmethoxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000212
5-(2-chloro-3-(cyclohexyloxy)benzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00002
5-(2-chloro-3-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00258
5-(2-chloro-3-(cyclopentyloxy)benzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000122
5-(2-chloro-3-phenethoxybenzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.000257
5-(3-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
0.00862
5-(3-(bicyclo[2.2.1]hept-2-ylmethoxy)-2-chlorobenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH 75, 37°C, recombinant GST-tagged enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Hansen, H.S.
Purification and assay of 15-ketoprostaglandin delta 13-reductase from bovine lung
Methods Enzymol.
86
156-167
1982
Bos taurus, Gallus gallus, Homo sapiens
brenda
Jarabak, J.
Isolation and properties of a 15-ketoprostaglandin delta 13-reductase from human placenta
Methods Enzymol.
86
163-167
1982
Homo sapiens
brenda
Westbrook, C.; Jarabak, J.
Purification and partial characterization of an NADH-linked delta13-15-ketoprostaglandin reductase from human placenta
Biochem. Biophys. Res. Commun.
66
541-546
1975
Homo sapiens
brenda
Hansen, H.S.
Purification and characterization of a 15-ketoprostaglandin delta 13-reductase from bovine lung
Biochim. Biophys. Acta
574
136-145
1979
Bos taurus
brenda
Westbrook, C.; Jarabak, J.
15-Ketoprostaglandin delta13 reductase from human placenta: purification, kinetics, and inhibitor binding
Arch. Biochem. Biophys.
185
429-442
1978
Homo sapiens
brenda
Nikaido, H.; Moriishi, M.; Mishima, H.K.; Kitamura, S.; Tatsumi, K.
15-Ketoprostaglandin delta 13-reductase activity in bovine ocular tissues
Curr. Eye Res.
12
17-22
1993
Bos taurus
brenda
Kitamura, S.; Katsura, H.; Tatsumi, K.
Purification of a 15-ketoprostaglandin DELTA13-reductase from rat liver and its ability to reduce the double bond of xenobiotics
Biochem. Mol. Biol. Int.
30
839-847
1993
Rattus norvegicus
brenda
Ensor, C.M.; Zhang, H.; Tai, H.H.
Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung
Biochem. J.
330
103-108
1998
Bos taurus, Sus scrofa
-
brenda
Clish, C.B.; Levy, B.D.; Chiang, N.; Tai, H.H.; Serhan, C.N.
Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-oxoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation
J. Biol. Chem.
275
25372-25380
2000
Sus scrofa
brenda
Yamamoto, T.; Yokomizo, T.; Nakao, A.; Izumi, T.; Shimizu, T.
Immunohistochemical localization of guinea-pig leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin 13-reductase
Eur. J. Biochem.
268
6105-6113
2001
Cavia porcellus
brenda
Dick, R.A.; Kwak, M.K.; Sutter, T.R.; Kensler, T.W.
Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase. A new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase
J. Biol. Chem.
276
40803-40810
2001
Rattus norvegicus
brenda
Hori, T.; Yokomizo, T.; Ago, H.; Sugahara, M.; Ueno, G.; Yamamoto, M.; Kumasaka, T.; Shimizu, T.; Miyano, M.
Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop
J. Biol. Chem.
279
22615-22623
2004
Cavia porcellus
brenda
Hori, T.; Ishijima, J.; Yokomizo, T.; Ago, H.; Shimizu, T.; Miyano, M.
Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy
J. Biochem.
140
457-466
2006
Cavia porcellus
brenda
Chou, W.L.; Chuang, L.M.; Chou, C.C.; Wang, A.H.; Lawson, J.A.; FitzGerald, G.A.; Chang, Z.F.
Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation
J. Biol. Chem.
282
18162-18172
2007
Mus musculus (Q8VDQ1)
brenda
Itoh, K.; Yamamoto, K.; Adachi, M.; Kosaka, T.; Tanaka, Y.
Leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin DELTA13-reductase (LTB4 12-HD/PGR) responsible for the reduction of a double-bond of the alpha,beta-unsaturated ketone of an aryl propionic acid non-steroidal anti-inflammatory agent CS-670
Xenobiotica
38
249-263
2008
Rattus norvegicus
brenda
Zhao, Y.; Weng, C.C.; Tong, M.; Wei, J.; Tai, H.H.
Restoration of leukotriene B(4)-12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase (LTBDH/PGR) expression inhibits lung cancer growth in vitro and in vivo
Lung Cancer
68
161-169
2010
Sus scrofa (Q29073)
brenda
Mesa, J.; Alsina, C.; Oppermann, U.; Pares, X.; Farres, J.; Porte, S.
Human prostaglandin reductase 1 (PGR1) Substrate specificity, inhibitor analysis and site-directed mutagenesis
Chem. Biol. Interact.
234
105-113
2015
Homo sapiens (P15428), Homo sapiens
brenda
Piao, Y.; Wu, Y.; Seo, S.; Lim, S.; Cho, H.
Wound healing effects of new 15-hydroxyprostaglandin dehydrogenase inhibitors
Prostaglandins Leukot. Essent. Fatty Acids
91
325-332
2014
Homo sapiens
brenda